12:00 AM
 | 
Jan 12, 2009
 |  BioCentury  |  Finance

New products to watch

New products to watch

Selected drugs that received regulatory approval in 2008.

Company Product Indication 2008 approval
Abbott (NYSE:ABT) Simcor extended-release niacin / immediate-release simvastatin Manage cholesterol in patients with complex lipid disease when treatment with either therapy alone is not adequate U.S.
Adolor (NASDAQ:ADLR)/ GlaxoSmithKline (LSE:GSK; NYSE:GSK) Entereg alvimopan Postoperative ileus (POI) U.S.
Alcon (NYSE:ACL) Patanase olopatadine hydrochloride nasal spray Seasonal allergic rhinitis U.S.
Allergan (NYSE:AGN) Trivaris triamcinolone Intravitreal, intramuscular or intra-articular injection to treat sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids U.S.
Allergan (NYSE:AGN) Latisse bimatoprost ophthalmic solution 0.03% Hypotrichosis of the eyelashes U.S.
Amgen (NASDAQ:AMGN) Nplate romiplostim Thrombocytopenia in adults with idiopathic thrombocytopenic purpura (ITP) U.S.
Antisoma (LSE:ASM) Oral fludarabine B cell chronic lymphocytic leukemia (B CLL) U.S.
Bayer (Xetra:BAY)/ J&J (NYSE:JNJ) Xarelto rivaroxaban Prevent venous thromboembolic...

Read the full 1190 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >